First-Half 2026 Results

Marcy l’Etoile (France), July 28, 2026 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on July 27, under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2026.

Key highlights :

• +0.2% organic sales growth in H1 26, at €1,965 million driven by a +6% organic sales increase across the four growth drivers of the GO•28 strategic plan while the sales of the BIOFIRE^® respiratory panels were negatively impacted by a lower respiratory epidemiology in H1 26 versus H1 25:
  • Microbiology: +4.3% organic sales growth, supported by strong momentum in reagent sales, particularly BACT/ALERT^® bottles;
  • SPOTFIRE^®: €90 million in revenues with reagents sales up 35% despite a lower respiratory epidemiology than in the prior year period;
  • BIOFIRE^® non-respiratory panels: +5.5% organic sales growth, with acceleration in Q2 2026;
  • Industrial Applications: +7% organic sales growth, driven by double-digit growth in reagents sales;
  • BIOFIRE^® respiratory panels: -17% organic sales decline, reflecting a significantly softer respiratory epidemiological activity in H1 26 compared to H1 25.

• Q2 2026 sales totaled €981 million, with solid organic growth at +5%, reaching +7% excluding BIOFIRE^® respiratory panels. The sales of the GO•28 growth drivers increased by 8.5% organically in Q2 26.
• Contributive operating income before non-recurring item (CEBIT) at €313 million in H1 26, including a €35m negative currency effect, and declining -4.9% organically versus H1 25.
• Net income (group share) amounted to €226 million, up 41% compared to H1 2025 which was impacted by the partial impairment of the VITEK^® REVEAL™ technology.
• Adjusted diluted earnings per share (Adjusted EPS) of €1.99, -4% organically and -17% reported versus H1 2025.
• Free cash-flow generation up 76% in H1 2026 versus H1 2025, at €299 million.
• Based on the solid organic sales growth in Q2 2026, bioMérieux confirms its 2026 guidance with organic sales growth expected between +3% and +5% and organic CEBIT growth between +0% to +10%. The negative currency effect on full-year 2026 CEBIT is now expected to be €40-50 million, versus the previously anticipated €50-60 million.
• In 2026 and beyond, bioMérieux will continue to execute on the four pillars of its GO•28 strategic plan. However, considering the change in geopolitical and macroeconomic environment since 2024, bioMérieux is adjusting its midterm financial outlook. Accordingly, for 2027 and 2028, bioMérieux is aiming at delivering +3% to +6% organic annual sales growth (versus “7% CAGR 2024/2028” previously) and organic annual CEBIT growth higher than organic sales growth (versus “at least +10%” previously).

Pierre Boulud, Chief Executive Officer, said: “After a first quarter significantly impacted by a low respiratory season, the second quarter marked an important quarter for bioMérieux, with solid sales growth and key milestones achievements with the FDA submission of the SPOTFIRE^® vaginitis panel and the CE marking of the first SPINCHIP^® assay. In line with the solid Q2 performance, we are confirming our 2026 guidance. At the same time, to reflect the change in the geopolitical and macroeconomic environment, we have decided to adjust our outlook for 2027 and 2028. The fundamentals of our business remain strong and our innovation pipeline will continue to support future growth, while we pursue the execution of the different dimensions of the GO•28 strategic plan.”